References
1a
Cao S.-G.
Wu X.-H.
Sim K.-Y.
Tan BHK.
Vittal JJ.
Pereira JT.
Goh S.-H.
Helv. Chim. Acta
1998,
81:
1404
1b
Ito A.
Chai H.-B.
Shin YG.
García R.
Mejía M.
Gao Q.
Fairchild CR.
Lane KE.
Menendez AT.
Farnsworth NR.
Cordell GA.
Pezzuto JM.
Kinghorn AD.
Tetrahedron
2000,
56:
6401
1c
Guilet D.
Seraphin D.
Rondeau D.
Richomme P.
Bruneton J.
Phytochemistry
2001,
58:
571
1d
Chaturvedula VSP.
Schilling JK.
Kingston DGI.
J. Nat. Prod.
2002,
65:
965
1e
Jenett-Siems K.
Kohler I.
Kraft C.
Beyer G.
Melzig MF.
Eich E.
Pharmazie
2002,
57:
351
2
Itoigawa M.
Ito C.
Tan HT.-W.
Kuchide M.
Tokuda H.
Nishino H.
Furukawa H.
Cancer Lett.
2001,
169:
15
3
Bailly C.
Bal C.
Barbier P.
Combes S.
Finet J.-P.
Hildebrand M.-P.
Peyrot V.
Wattez N.
J. Med. Chem.
2003,
46:
5437
4a
Jordan MA.
Curr. Med. Chem.: Anti-Cancer Agents
2002,
2:
1
4b
Jordan A.
Hadfield JA.
Lawrence NJ.
McGown AT.
Med. Res. Rev.
1998,
18:
259
4c
Hamel E.
Med. Res. Rev.
1996,
16:
207
5a
Pettit GR.
Singh SB.
Boyd MR.
Hamel E.
Pettit RK.
Schmidt JM.
Hogan F.
J. Med. Chem.
1995,
38:
1666
5b
Gaukroger K.
Hadfield JA.
Hepworth LA.
Lawrence NG.
McGown AT.
J. Org. Chem.
2001,
66:
8135
6a
Boyle FT.
Costello GF.
Chem. Soc. Rev.
1998,
27:
251
6b
Chang YC.
Nair MG.
Nitiss JL.
J. Nat. Prod.
1995,
58:
1901
6c
Dixon RA.
Ferreira D.
Phytochemistry
2002,
60:
205
7a
Jones GH.
Mackenzie JBD.
Robertson A.
Whalley WB.
J. Chem. Soc.
1949,
562
7b
Barton DHR.
Donnelly DMX.
Finet J.-P.
Guiry PJ.
J. Chem. Soc., Perkin Trans. 1
1992,
1365
7c
Combes S.
Finet J.-P.
Siri D.
J. Chem. Soc., Perkin Trans. 1
2002,
38
8a
Boland GM.
Donnelly DMX.
Finet J.-P.
Rea MD.
J. Chem. Soc., Perkin Trans. 1
1996,
2591
8b
Donnelly DMX.
Finet J.-P.
Guiry PJ.
Rea MD.
Synth. Commun.
1999,
29:
2719
9a
Wattanasin S.
Synth. Commun.
1988,
18:
1919
9b
Schio L.
Chatreaux F.
Klich M.
Tetrahedron Lett.
2000,
41:
1543
10
Wu J.
Liao Y.
Yang Z.
J. Org. Chem.
2001,
66:
3642
11a
Miyaura N.
Suzuki A.
Chem. Rev.
1995,
95:
2457
11b
Suzuki A.
J. Organomet. Chem.
1999,
576:
147
11c
Hassan J.
Sevignon M.
Gozzi C.
Schultz E.
Lemaire M.
Chem. Rev.
2002,
102:
1359
11d
Kotha S.
Lahiri K.
Kashinath D.
Tetrahedron
2002,
58:
9633
12
General Procedure: A mixture of 4-trifluoromethyl-sulfonyloxycoumarin (0.15-0.4 mmol, 1 equiv), heteroarylboronic acid (1.3 equiv), K3PO4 (3.00 equiv), Bu4NBr (0.1 equiv) and PdCl2(dppf) (0.05 equiv) in dry MeCN (1-2 mL), under argon atmosphere, was heated at reflux until the 4-trifluoromethylsulfonyloxycoumarin was completely consumed (0.5-3 h, monitored by TLC). The mixture was diluted with H2O and extracted with CH2Cl2. The organic layer was dried (Na2SO4), and after distillation of the solvent, the residue was purified by column chromatography on silica gel (EtOAc-petroleum ether = 3:2) to give the corresponding products.
The heteroarylboronic acids 2a-c were obtained from Lancaster and used as received. The 2,4-dibenzyloxy-3,5-pyrimidylboronic acid (2d) was prepared by the procedure of:
13a
Schinazi RF.
Prusoff W.
Tetrahedron Lett.
1978,
19:
4981
13b
Schinazi RF.
Prusoff W.
J. Org. Chem.
1985,
50:
841 ; it can also be obtained from Khimmed (Kashirskoe avenue, 115230 Moscow, Russia)
14
Selected Physical Data:
4-(3′-Quinolyl)-5,6,7-trimethoxycoumarin (
3c): white needles; mp 155 °C. 1H NMR: δ = 3.23, 3.77 and 3.95 (9 H, s, OCH3), 6.16 (1 H, s, H-3), 6.75 (1 H, s, H-8), 7.62 (1 H, td, J = 7.4 and 1.1 Hz, H-5′), 7.78 (1 H, td, J = 7.4 and 1.5 Hz, H-6′), 7.88 (1 H, d, J = 8.3 Hz, H-7′), 8.13 (1 H, d, J = 2.2 Hz, H-8′), 8.18 (1 H, d, J = 8.3 Hz, H-4′), 8.89 (1 H, d, J = 2.2 Hz, H-2′). 13C NMR: δ = 56.4, 60.8 and 61.1 (OCH3), 96.4, 106.7, 115.0, 127.0, 127.3, 128.0, 129.1, 130.1, 132.3, 133.2, 139.2, 147.0, 149.5, 150.8, 151.7, 151.9, 157.4, 160.2. MS: m/z (%) = 363 (100) [M+], 348 (56), 332 (10), 320 (14), 277 (12), 262 (13).
4-(2′-Furyl)-5,6,7-trimethoxycoumarin (
4c): yellow needles; mp 116 °C; 1H NMR: δ = 3.62, 3.83 and 3.92 (9 H, s, OCH3), 6.35 (1 H, s, H-3), 6.51 (1 H, dd, J = 3.4 and 1.5 Hz, H-4′), 6.69 (1 H, s, H-8), 6.74 (1 H, d, J = 3.4 Hz, H-5′), 7.56 (1 H, d, J = 1.5 Hz, H-3′). 13C NMR: δ = 56.2, 61.1 and 61.8 (OCH3), 96.3, 105.8, 111.4, 112.0, 113.4, 139.4, 142.9, 143.7, 149.9, 150.8, 151.8, 156.8, 160.6. MS: m/z (%) = 302 (100) [M+], 287 (18), 274 (20), 259 (100), 231 (13), 216 (23), 201 (19).
4-(4′-Methoxy-3′-pyridinyl)-5,6,7-trimethoxycoumarin (
5c): white needles; mp 164 °C. 1H NMR: δ = 3.31, 3.80, 3.93 and 3.98 (12 H, s, OCH3), 6.05 (1 H, s, H-3), 6.72 (1 H, s, H-8), 7.77 (1 H, dd, J = 8.6 and 0.9 Hz, H-5′), 7.59 (1 H, dd, J = 8.8 and 2.5 Hz, H-6′), 8.14 (1 H, d, J = 2.5 Hz, H-2′). 13C NMR: δ = 53.5, 56.2, 60.8 and 61.0 (OCH3), 96.4, 106.9, 107.6, 109.3, 114.3, 127.8, 138.6, 139.4, 144.5, 150.8, 151.7, 156.9, 160.2 (C2), 164.0 (C4′). MS: m/z (%) = 343 (100) [M+], 328 (54), 315 (8), 300(15), 257 (8).
4-(2′,4′-Dibenzyloxy-3′,5′-pyrimidinyl)-5,6,7-trimethoxycoumarin (
6c): white needles; mp 139 °C. 1H NMR: δ = 3.31, 3.63, and 3.89 (9 H, s, OCH3), 5.48 (4 H, s, CH2), 6.06 (1 H, s, H-3), 6.67 (1 H, s, H-8), 7.11-7.49 (10 H, m, ArH), 8.15 (1 H, s, H-6′). 13C NMR: δ = 56.3, 60.8 and 61.1 (OCH3), 68.4 and 69.4 (CH2), 96.2, 107.1, 114.4, 115.3, 127.2, 127.9, 128.0, 128.1, 128.3, 128.4, 135.6, 136.3, 139.0, 147.3, 150.7, 151.2, 154.4, 156.8, 160.3, 164.8, 167.9.